At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
gamma-secretase/Notch signalling pathway inhibitor RO4929097 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Study of RO4929097 in Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating gamma-secretase/Notch signalling pathway inhibitor RO4929097 and laboratory biomarker analysis for Recurrent Colon Cancer and 3 related conditions. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This phase II trial studies how well RO4929097 works in treating patients with metastatic colorectal cancer. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionMay 2011
Study CompletionMar 2012
TodayJul 2026
First PostedMay 5, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.2 years ago
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097drug
Given orally
laboratory biomarker analysisother
Correlative studies